HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A distinct [18F]MPPF PET profile in amnestic mild cognitive impairment compared to mild Alzheimer's disease.

Abstract
To date, two positron emission tomography (PET) studies have explored 5-HT(1A) receptor density in the hippocampus of Alzheimer's disease (AD) patients. They showed early changes of 5-HT(1A) receptors in this brain region, known to have a dense serotonergic innervation. These studies only reported measurements in hippocampus. In the present PET study, we used an antagonist of 5-HT(1A) receptors, the [(18)F]MPPF (1) to explore 5-HT(1A) receptor density in the whole brain of AD patients at a mild stage of dementia and amnestic mild cognitive impairment (aMCI) patients compared to a control population; (2) to explore more precisely the 5-HT(1A) receptor density in the limbic brain regions of AD patients and aMCI patients compared to controls. Voxel-based analyses were performed to assess differences in the [(18)F]MPPF binding potential (BP) between AD patients and aMCI patients compared to controls. Analyses of whole-brain [(18)F]MPPF BP showed a global decrease in AD brains in contrast with a global increase in aMCI brains. In AD brains, a significant decrease of BP was detected in hippocampus and parahippocampal gyrus, whereas a significant increase of BP was observed in the inferior occipital gyrus in aMCI brains. These whole brain results are in accordance to hippocampal data reported in a previous study, showing an increase of [(18)F]MPPF binding in the aMCI group contrasting with a decrease in the AD group. Altogether, these results suggest the implication of a compensatory mechanism illustrated by an up regulation of serotonergic metabolism at the aMCI stage before a breakdown of this mechanism at the AD stage. This difference of serotonergic receptor labeling allows to distinguish the groups of aMCI patients from mild AD patients with specific [(18)F]MPPF PET profiles for each patient group.
AuthorsL Truchot, N Costes, L Zimmer, B Laurent, D Le Bars, C Thomas-Antérion, B Mercier, M Hermier, A Vighetto, P Krolak-Salmon
JournalNeuroImage (Neuroimage) Vol. 40 Issue 3 Pg. 1251-6 (Apr 15 2008) ISSN: 1053-8119 [Print] United States
PMID18313943 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Piperazines
  • Pyridines
  • Radiopharmaceuticals
  • Receptor, Serotonin, 5-HT1A
  • 4-(2'-methoxyphenyl)-1-(2'-(N-2'-pyridinyl)-p-(18F)fluorobenzamido )ethylpiperazine
Topics
  • Aged
  • Alzheimer Disease (diagnostic imaging, psychology)
  • Amnesia (diagnostic imaging, psychology)
  • Brain (diagnostic imaging)
  • Cognition Disorders (diagnostic imaging, psychology)
  • Female
  • Functional Laterality (physiology)
  • Humans
  • Image Processing, Computer-Assisted
  • Limbic System (diagnostic imaging)
  • Male
  • Middle Aged
  • Piperazines
  • Positron-Emission Tomography
  • Pyridines
  • Radiopharmaceuticals
  • Receptor, Serotonin, 5-HT1A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: